Increased urinary leukotriene E 4 concentration in patients with eosinophilic

Although eosinophils produce cysteinyl leukotrienes (CysLTs) in large quantities, information on the relationship between CysLTs and eosinophilic pneumonia (EP) is lacking. Inflammatory mediator concentrations in urine were quantified to clarify the relationship between CysLT concentrations and EP severity. Leukotriene (LT)E4, eosinophil-derived neurotoxin (EDN), 9a,11b-prostaglandin F2 and LTB4 glucuronide concentrations were quantified in the urine of: EP patients during acute exacerbation and clinical remission; asthmatic patients during acute exacerbation and under stable conditions; and healthy control subjects. The urinary LTE4 and EDN concentrations of EP patients during acute exacerbation were significantly higher than those of asthmatic patients and healthy subjects, and decreased immediately during clinical remission. The urinary LTE4 concentration was associated with the urinary EDN concentration of EP patients during acute exacerbation. The urinary LTE4 concentration significantly correlated with the diffusing capacity of the lung for carbon monoxide in EP patients during acute exacerbation. The increased urinary concentrations of leukotriene and eosinophil-derived neurotoxin were associated with acute exacerbation in eosinophilic pneumonia patients. The increased leukotriene concentration significantly correlated with diffusing capacity of the lung for carbon monoxide, suggesting that the monitoring of leukotriene concentration may aid in the manage- ment of eosinophilic pneumonia patients.

[1]  M. Taniguchi,et al.  Quantification of leukotriene B4 glucuronide in human urine. , 2007, Prostaglandins & other lipid mediators.

[2]  J. Hankinson,et al.  Standardisation of the single-breath determination of carbon monoxide uptake in the lung , 2005, European Respiratory Journal.

[3]  S. Anderson,et al.  Evidence of mast cell activation and leukotriene release after mannitol inhalation , 2003, European Respiratory Journal.

[4]  A. Menzies-Gow,et al.  Eosinophils and interleukin-5: the debate continues. , 2003, American journal of respiratory and critical care medicine.

[5]  Keiko Saito,et al.  The Roles of Cysteinyl Leukotrienes in Eosinophilic Inflammation of Asthmatic Airways , 2003, International Archives of Allergy and Immunology.

[6]  N. Higashi,et al.  A comparative study of eicosanoid concentrations in sputum and urine in patients with aspirin‐intolerant asthma , 2002, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[7]  P. O'Byrne,et al.  Cysteinyl leukotrienes promote human airway smooth muscle migration. , 2002, American journal of respiratory and critical care medicine.

[8]  I. Pavord,et al.  Sputum cysteinyl leukotrienes increase 24 hours after allergen inhalation in atopic asthmatics. , 2000, American journal of respiratory and critical care medicine.

[9]  H. Mita,et al.  Efficient method for the quantitation of urinary leukotriene E4: extraction using an Empore C18 disk cartridge. , 1997, Journal of chromatography. B, Biomedical sciences and applications.

[10]  A. Ammit,et al.  Mast cell numbers are increased in the smooth muscle of human sensitized isolated bronchi. , 1997, American journal of respiratory and critical care medicine.

[11]  M. Kumlin.  Measurements of leukotrienes in the urine: strategies and applications , 1997, Allergy.

[12]  S. Dahlén,et al.  Increased urinary excretion of the prostaglandin D2 metabolite 9 alpha, 11 beta-prostaglandin F2 after aspirin challenge supports mast cell activation in aspirin-induced airway obstruction. , 1996, The Journal of allergy and clinical immunology.

[13]  I. Strannegård,et al.  Urinary eosinophil protein X in children with atopic asthma: a useful marker of antiinflammatory treatment. , 1996, The Journal of allergy and clinical immunology.

[14]  H. Kita,et al.  Cytokine production at the site of disease in chronic eosinophilic pneumonitis. , 1996, American journal of respiratory and critical care medicine.

[15]  J. N. Allen,et al.  Eosinophilic lung diseases. , 1994, American journal of respiratory and critical care medicine.

[16]  R. Braun,et al.  Activated T cells and cytokines in bronchoalveolar lavages from patients with various lung diseases associated with eosinophilia. , 1994, American journal of respiratory and critical care medicine.

[17]  J. Bousquet,et al.  Eosinophilic and neutrophilic inflammation in asthma, chronic bronchitis, and chronic obstructive pulmonary disease. , 1993, The Journal of allergy and clinical immunology.

[18]  J. Bousquet,et al.  Eosinophilic inflammation in asthma. , 1990, The New England journal of medicine.

[19]  E. Pacht,et al.  Acute eosinophilic pneumonia as a reversible cause of noninfectious respiratory failure. , 1989, The New England journal of medicine.

[20]  F. Ogushi,et al.  PGE2 and PGF2 alpha content in bronchoalveolar lavage fluid obtained from patients with eosinophilic pneumonia. , 1987, Chest.

[21]  T. McLoud,et al.  Normal chest roentgenograms in chronic diffuse infiltrative lung disease. , 1978, The New England journal of medicine.

[22]  C. Carrington,et al.  Chronic eosinophilic pneumonia. , 1969, The New England journal of medicine.